The role of the dioxin-responsive element cluster between the Cyp1a1 and Cyp1a2 loci in aryl hydrocarbon receptor biology

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 12, 2009, Pages 4923-4928

  Nukaya, Manabu ^a   Moran, Susan ^a   Bradfield, Christopher A ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

AHR; Cyp1a1; Cyp1a2; Cytochrome; DRE; P450

Indexed keywords

ALANINE AMINOTRANSFERASE; AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; DIOXIN; SPACER DNA; 2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN;

ACUTE TOXICITY; ADAPTATION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID SEQUENCE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DUCTUS VENOSUS; GENE CLUSTER; GENE LOCUS; GENETIC MODEL; HEART WEIGHT; HEPATITIS; HOMOLOGOUS RECOMBINATION; IN VIVO STUDY; KIDNEY MASS; LIVER BLOOD VESSEL; LIVER INJURY; LIVER PROTECTION; LIVER TOXICITY; LIVER WEIGHT; LUNG WEIGHT; MALE; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NULL ALLELE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN WEIGHT; TRANSCRIPTION INITIATION SITE; UPREGULATION; VASCULAR PATENCY; ALLELE; ANIMAL; BIOSYNTHESIS; DRUG EFFECT; ENZYME INDUCTION; ENZYMOLOGY; GENE DELETION; GENETICS; HEPATIC ARTERY; LIVER DISEASE; LIVER VEIN; METABOLISM; MOUSE MUTANT; PATHOLOGY; PRENATAL DEVELOPMENT;

MUS;

ALLELES; ANIMALS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; ENZYME INDUCTION; HEPATIC ARTERY; HEPATIC VEINS; LIVER DISEASES; MALE; MICE; MICE, KNOCKOUT; RECEPTORS, ARYL HYDROCARBON; RESPONSE ELEMENTS; SEQUENCE DELETION; TETRACHLORODIBENZODIOXIN;

EID: 63849137120     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0809613106     Document Type: Article

References (50)

1. Hankinson O (1995) The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol 35:307-340.
2. Schmidt JV, Su GH, Reddy JK, Simon MC, Bradfield CA (1996) Characterization of a murine Ahrnull allele: Involvement of the Ah receptor in hepatic growth and development. Proc Natl Acad Sci USA 93:6731-6736.
3. Whitlock JP, Jr, et al. (1997) Induction of drug-metabolizing enzymes by dioxin. Drug Metab Rev 29:1107-1127.
4. Nebert DW, Gonzalez FJ (1987) P450 genes: Structure, evolution, and regulation. Annu Rev Biochem 56:945-993.
5. Gu YZ, Hogenesch JB, Bradfield CA (2000) The PAS superfamily: Sensors of environmental and developmental signals. Annu Rev Pharmacol Toxicol 40:519-561.
6. Pohjanvirta R, Tuomisto J (1994) Short-term toxicity of 2,3,7,8-tetrachlorodibenzo-p- dioxin in laboratory animals: Effects, mechanisms, and animal models. Pharmacol Rev 46:483-549.
7. Lahvis GP, et al. (2000) Portosystemic shunting and persistent fetal vascular structures in aryl hydrocarbon receptor-deficient mice. Proc Natl Acad SciUSA 97:10442-10447.
8. Bunger MK, et al. (2003) Resistance to 2,3,7,8-tetrachlorodibenzo-p-dioxin toxicityand abnormal liver development in mice carrying a mutation in the nuclear localization sequence of the aryl hydrocarbon receptor. J Biol Chem 278:17767-17774.
9. Walisser JA, Bunger MK, Glover E, Bradfield CA(2004) Gestational exposure of Ahr and Arnt hypomorphs to dioxin rescues vascular development. Proc Natl Acad Sci USA 101:16677-16682.
10. Harstad EB, Guite CA, Thomae TL, Bradfield CA (2006) Liver deformation in Ahr-null mice: Evidence for aberrant hepatic perfusion in early development. Mol Pharmacol 69:1534-1541.
11. Sun YV, Boverhof DR, Burgoon LD, Fielden MR, Zacharewski TR (2004) Comparative analysis of dioxin response elements in human, mouse and rat genomic sequences. Nucleic Acids Res 32:4512-4523.
12. Nelson DR, et al. (1996) P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-43.
13. Yang SK (1988) Stereoselectivityof cytochrome P-450 isozymes and epoxide hydrolase in the metabolism of polycyclic aromatic hydrocarbons. Biochem Pharmacol 37:61-70.
14. Hayes KR, et al. (2005) EDGE: A centralized resource for the comparison, analysis, and distribution of toxicogenomic information. Mol Pharmacol 67:1360-1368.
15. Hayes KR, et al. (2007) Hepatic transcriptional networks induced by exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Chem Res Toxicol 20:1573-1581.
16. Whysner J, Williams GM (1996) 2,3,7,8-Tetrachlorodibenzo-p-dioxin mechanistic data and risk assessment: Gene regulation, cytotoxicity, enhanced cell proliferation, and tumor promotion. Pharmacol Ther 71:193-223.
17. Andersen ME, Barton HA (1998) The use of biochemical and molecular parameters to estimate dose-response relationships at low levels of exposure. Environ Health Perspect 106:349-355.
18. Schwarz M, Appel KE (2005) Carcinogenic risks of dioxin: Mechanistic considerations. Regul Toxicol Pharmacol 43:19-34.
19. Ma Q, Lu AY (2007) CYP1A induction and human risk assessment: An evolving tale of in vitro and in vivo studies. Drug Metab Dispos 35:1009-1016.
20. Uno S, et al. (2004) Cyp1a1(-/-) male mice: Protection against high-dose TCDD-induced lethality and wasting syndrome, and resistance to intrahepatocyte lipid accumulation and uroporphyria. Toxicol Appl Pharmacol 196:410-421.
21. Smith AG, et al. (2001) Protection of the Cyp1a2(-/-) null mouse against uroporphyria and hepatic injuryfollowing exposure to 2,3,7,8-tetrachlorodibenzo- p-dioxin. Toxicol Appl Pharmacol 173:89-98.
22. Nukaya M, Bradfield CA (2009) Conserved genomic structure of the Cyp1a1 and Cyp1a2 loci and their dioxin-responsive elements cluster. Biochem Pharmacol 77:654-659.
23. CorcheroJ,PimpraleS,KimuraS,GonzalezFJ (2001)Organization oftheCYP1Aclusteron human chromosome 15: Implications for gene regulation. Pharmacogenetics11:1-6.
24. Whitlock JP, Jr (1999) Induction of cytochrome P4501A1. Annu Rev Pharmacol Toxicol 39:103-125.
25. Kress S, Reichert J, Schwarz M (1998) Functional analysis of the human cytochrome P4501A1 (CYP1A1 ) gene enhancer. Eur J Biochem 258:803-812.
26. Fujii-Kuriyama Y, Imataka H, Sogawa K, Yasumoto K, Kikuchi Y (1992) Regulation of CYP1A1 expression. FASEB J 6:706-710.
27. Strom DK, Postlind H, Tukey RH (1992) Characterization of the rabbit CYP1A1 and CYP1A2 genes: Developmental and dioxin-inducible expression ofrabbitliver P4501A1 and P4501A2. Arch Biochem Biophys 294:707-716.
28. Zeruth G, Pollenz RS(2005)Isolation and characterization ofa dioxin-inducibleCYP1A1 promoter/enhancer region from zebrafish (Danio rerio). Zebrafish 2:197-210.
29. Owens RA, Nebert DW (1990) Expression of the chloramphenicol acetyltransferase (CAT) reporter gene by the murine Cyp1a-2 (cytochrome P3(450)) promoter in hepatoma cell cultures. Biochem Biophys Res Commun 172:1109-1115.
30. Ueda R, et al. (2006) A common regulatory region functions bidirectionally in transcriptional activation of the human CYP1A1 and CYP1A2 genes. Mol Pharmacol 69:1924-1930.
31. Lin BC, et al. (2007) Deletion of the aryl hydrocarbon receptor-associated protein 9 leads to cardiac malformation and embryonic lethality. J Biol Chem 282:35924-35932.
32. Dymecki S (1996) Flp recombinase promotes site-specific DNA recombination in embryonic stem cells and transgenic mice. Proc Natl Acad Sci USA 93:6191-6196.
33. Farley FW, Soriano P, Steffen LS, Dymecki SM (2000) Widespread recombinase expression using FLPeR (flipper) mice. Genesis 28:106-110.
34. Hoess R, Wierzbicki A, Abremski K(1986) The role of the spacer region in P1 site-specific recombination. Nucleic Acids Res 14:2287-2300.
35. Sternberg N, Hoess R (1983) The molecular genetics of bacteriophage P1. Annu Rev Genet 17:123-154.
36. Schwenk F, Baron U, Rajewsky KA (1995) A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res 23:5080-5081.
37. Walisser JA, Glover E, Pande K, Liss AL, Bradfield CA (2005) Aryl hydrocarbon receptor- dependent liver development and hepatotoxicity are mediated by different cell types. Proc Natl Acad Sci USA 102:17858-17863.
38. Walisser JA, Bunger MK, Glover E, Harstad EB, Bradfield CA (2004) Patent ductus venosus and dioxin resistance in mice harboring a hypomorphic Arnt allele. J Biol Chem 279:16326-16331.
39. Pande K, Moran SM, Bradfield CA (2005) Aspects of dioxin toxicity are mediated by interleukin 1-like cytokines. Mol Pharmacol 67:1393-1398.
40. -/-) null mutant mice develop normally but show deficient drug metabolism. Proc Natl Acad Sci USA 93:1671-1676.
41. Dalton TP, et al. (2000) Targeted knockout of Cyp1a1 gene does not alter hepatic constitutive expression of other genes in the mouse [Ah] battery. Biochem Biophys Res Commun 267:184-189.
42. Jones KW, Whitlock JP, Jr (1990) Functional analysis of the transcriptional promoter for the CYP1A1 gene. Mol Cell Biol 10:5098-5105.
43. Quattrochi LC, Vu T, Tukey RH (1994) The human CYP1A2 gene and induction by 3-methylcholanthrene: A region of DNA that supports AH receptor binding and promoter-specific induction. J Biol Chem 269:6949-6954.
44. Lin BC, Nguyen LP, Walisser JA, Bradfield CA (2008) A hypomorphic allele of aryl hydrocarbon receptor-associated protein-9 produces a phenocopy of the AHR-null mouse. Mol Pharmacol 74:1367-1371.
45. Crawford JM (2005) in Robbins and Cotran Pathologic Basis of Disease, eds Kumar V, Abbas AK, Fausto N (Saunders, Philadelphia, PA), 7th Ed, pp 880-882.
46. Lucier GW, et al. (1973) TCDD-induced changes in rat liver microsomal enzymes. Environ Health Perspect 5:199-209.
47. Fowler BA, Lucier GW, Brown HW, McDaniel OS (1973) Ultrastructural changes in rat liver cells following a single oral dose of TCDD. Environ Health Perspect 5:141-148.
48. Thomas RS, Penn SG, Holden K, Bradfield CA, Rank DR (2002) Sequence variation and phylogenetic history of the mouse Ahr gene. Pharmacogenetics 12:151-163.
49. Bunger MK, et al. (2008) Abnormal liver development and resistance to 2,3,7,8- tetrachlorodibenzo-p-dioxin toxicity in mice carrying a mutation in the DNA-binding domain of the aryl hydrocarbon receptor. Toxicol Sci 106:83-92.
50. Hamm JT, Ross DG, Richardson VM, Diliberto JJ, Birnbaum LS (1998) Methoxyresorufin: An inappropriate substrate for CYP1A2 in the mouse. Biochem Pharmacol 56:1657-1660.